Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERSTELLAR: OFS + Endocrine Therapy in Low Genomic Risk Breast Cancer
NCT05333328Phase 4Recruiting
- Sponsor
- Gangnam Severance Hospital
- Start
- Feb 2023
- Primary completion
- Jan 2031
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of goserelin, leuprolide and tamoxifen in breast cancer, sponsored by Gangnam Severance Hospital. Primary endpoint: Distant recurrence-free survival at 5 years. Started Feb 2023; status: recruiting.
02
Drugs
goserelinleuprolidetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05333328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333328.